Market Cap 1.37B
Revenue (ttm) 49.08M
Net Income (ttm) -109.52M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -223.15%
Debt to Equity Ratio 0.00
Volume 2,247,500
Avg Vol 3,210,964
Day's Range N/A - N/A
Shares Out 51.22M
Stochastic %K 47%
Beta -0.12
Analysts Sell
Price Target $29.17

Company Profile

KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation i...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 999 0075
Fax: 866 553 3269
Address:
200 Crossing Boulevard, Framingham, United States
TwongStocks
TwongStocks May. 13 at 11:28 AM
$KALV Tender offer has officially commenced https://www.sec.gov/Archives/edgar/data/1348911/000114036126020935/ny20071872x1_sctot.htm • Expires 1 minute after 11:59pm ET on June 10, unless extended. • At least 50% of outstanding shares must be tendered for deal to close. • Tender offer is $27.00 per share Full tender offer: https://www.sec.gov/Archives/edgar/data/1348911/000114036126020935/ny20071872x1_exa1a.htm
0 · Reply
Quantumup
Quantumup May. 13 at 11:12 AM
Citizens⬇️ $PHVS's PT to $74 (was $75), reiterated at a Market Outperform, and said: The Phase 3 CHAPTER-3 readout coming in 3Q26 is the next key catalyst for shares. $KALV $BCRX IONS TAK Citizens added—In Phase 2, deucrictibant showed an ~85% attack reduction, which is in line with injectable prophylactics. If confirmed in Phase 3, deucrictibant XR could emerge as a differentiated oral option in an increasingly competitive HAE landscape. Meanwhile, the acute franchise is de-risked with robust RAPIDe-3 data supporting an NDA submission this quarter. We assign deucrictibant a POS of 90% for HAE treatment and 70% in HAE prophylaxis, with peak sales of~$950M and ~ $1.6B, respectively.
0 · Reply
TwongStocks
TwongStocks May. 12 at 7:45 PM
$KALV Still waiting on Chiesi to commence the tender offer. Per the 8-K, Chiesi has to initiate the tender offer within 10 business days of the merger agreement. https://www.sec.gov/ix?doc=/Archives/edgar/data/0001348911/000114036126017656/ef20071670_8k.htm "The Merger Agreement provides that Purchaser will commence the Offer no later than 10 business days after the date of the Merger Agreement." Merger agreement was signed Apr 29. If my count is right, ten business days is May 13. Cheisi needs to commence the tender offer by tomorrow.
0 · Reply
Pukkaa56
Pukkaa56 May. 11 at 6:47 AM
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech May. 7 at 6:03 PM
$CPRX M&A valuation as multiples of Year 4 (FY29), 5-year & 10-year revenue estimates versus peer commercial-stage biopharma M&A exits. Peer multiples are calculated using the revenue forecasts prepared by the management/BOD of the acquiree. $KALV & $APLS also use analyst consensus. NOTE CPRX is being acquired at one of the highest 10-year multiples (very likely because CPRX is a much more mature commercial-stage bio versus most of the peers). We're merely sharing our analysis. This is not investment advice. We cannot think of any peer like CPRX (that sold multiple therapies) except for $XERS which has patent life considerations $XBI
4 · Reply
JuggernautRaider
JuggernautRaider May. 4 at 2:11 PM
$SNDX looking juicy for a buyout! I called $KALV and I’m calling Syndax too - not invested currently but may buy dips. GLB ☘️ 🐂
2 · Reply
BearTamerTrading
BearTamerTrading May. 1 at 5:52 PM
$KALV Another Potential Rocket rises to the occasion again ! Congratulations to all members who had access a week in advance one month ago before the public. As always thank you for your trust. I will continue to deliver tremendous value and ROI for just 49.99 a month. I Don’t Miss ! https://youtu.be/ajTV9H8J8ew?si=RsseynwHmvBWjUQ9
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech May. 1 at 1:47 AM
$KALV 's $1.9B M&A enterprise value = 0.93X 5-year analyst consensus & 0.34X 10-year consensus. This appears right down the middle v. peer comm'l-stage M&A exits. The attached table calculates KALV's multiples using analyst consensus where the 11 peers use revenue forecasts prepared by the acquiree's mgnt/BOD. $SNDX has a new analyst providing revenue forecasts, which are now meaningfully higher than last week. SNDX's forecasts are now so high we don't believe they are credible but WTF do we know. We'll wait until analysts swallow today's update before reposting SNDX multiples. All the same, at $20/share SNDX's risk v reward profile is now quite compelling if analyst estimates are credible. SNDX $58MM in Q126 R&D or $200MM+/year? Let's hope there's a return SNDX 5-year consensus FY26-30 now = $3.94B per Seeking Alpha. Put a 0.90 or a 1.0X like KALV? Higher/lower? $ACAD $TARS $ARDX trade @ multiples meaningfully lower than peers (again if analyst estimates are credible). Much more to come.
4 · Reply
Vwill33
Vwill33 May. 1 at 12:45 AM
$KALV anyone looking into NUVB?
0 · Reply
RainyDayFund
RainyDayFund Apr. 30 at 6:21 PM
$KALV So we wait until deal closes and they pay us $27 per share?
1 · Reply
Latest News on KALV
KalVista downgraded to Hold from Buy at Stifel

2026-05-07T20:46:10.000Z - 5 days ago

KalVista downgraded to Hold from Buy at Stifel


KalVista downgraded to Neutral from Buy at H.C. Wainwright

2026-05-01T10:15:06.000Z - 12 days ago

KalVista downgraded to Neutral from Buy at H.C. Wainwright


KalVista downgraded to Hold from Buy at Needham

2026-04-30T17:36:53.000Z - 12 days ago

KalVista downgraded to Hold from Buy at Needham


KalVista downgraded to Hold from Buy at JonesResearch

2026-04-30T08:52:12.000Z - 13 days ago

KalVista downgraded to Hold from Buy at JonesResearch


KalVista moved to No Rating at BofA

2026-04-29T17:17:54.000Z - 13 days ago

KalVista moved to No Rating at BofA


Chiesi Group to acquire KalVista for $27.00 per share in cash

2026-04-29T12:15:08.000Z - 14 days ago

Chiesi Group to acquire KalVista for $27.00 per share in cash


Italian drugmaker Chiesi to buy KalVista for $1.9 billion

Apr 29, 2026, 7:53 AM EDT - 14 days ago

Italian drugmaker Chiesi to buy KalVista for $1.9 billion


KalVista price target lowered to $28 from $29 at Citizens

2026-03-26T09:55:42.000Z - 6 weeks ago

KalVista price target lowered to $28 from $29 at Citizens


KalVista price target raised to $42 from $39 at Stifel

2026-03-25T20:25:16.000Z - 6 weeks ago

KalVista price target raised to $42 from $39 at Stifel


KalVista Pharmaceuticals Transcript: Transition period

Mar 25, 2026, 8:30 AM EDT - 7 weeks ago

KalVista Pharmaceuticals Transcript: Transition period


KalVista price target raised to $35 from $30 at TD Cowen

2026-01-29T14:35:41.000Z - 3 months ago

KalVista price target raised to $35 from $30 at TD Cowen


KalVista price target raised to $37 from $27 at H.C. Wainwright

2026-01-09T11:10:40.000Z - 4 months ago

KalVista price target raised to $37 from $27 at H.C. Wainwright


KalVista price target raised to $29 from $28 at Citizens

2026-01-09T11:00:57.000Z - 4 months ago

KalVista price target raised to $29 from $28 at Citizens


KalVista Pharmaceuticals Earnings Call Transcript: Q3 2026

Nov 11, 2025, 8:30 AM EST - 6 months ago

KalVista Pharmaceuticals Earnings Call Transcript: Q3 2026


KalVista Pharmaceuticals Earnings Call Transcript: Q1 2026

Sep 11, 2025, 8:30 AM EDT - 8 months ago

KalVista Pharmaceuticals Earnings Call Transcript: Q1 2026


KalVista Pharmaceuticals Transcript: FDA Announcement

Jul 7, 2025, 8:30 AM EDT - 11 months ago

KalVista Pharmaceuticals Transcript: FDA Announcement


US FDA approves KalVista Pharma's swelling disorder drug

Jul 7, 2025, 6:37 AM EDT - 11 months ago

US FDA approves KalVista Pharma's swelling disorder drug


TwongStocks
TwongStocks May. 13 at 11:28 AM
$KALV Tender offer has officially commenced https://www.sec.gov/Archives/edgar/data/1348911/000114036126020935/ny20071872x1_sctot.htm • Expires 1 minute after 11:59pm ET on June 10, unless extended. • At least 50% of outstanding shares must be tendered for deal to close. • Tender offer is $27.00 per share Full tender offer: https://www.sec.gov/Archives/edgar/data/1348911/000114036126020935/ny20071872x1_exa1a.htm
0 · Reply
Quantumup
Quantumup May. 13 at 11:12 AM
Citizens⬇️ $PHVS's PT to $74 (was $75), reiterated at a Market Outperform, and said: The Phase 3 CHAPTER-3 readout coming in 3Q26 is the next key catalyst for shares. $KALV $BCRX IONS TAK Citizens added—In Phase 2, deucrictibant showed an ~85% attack reduction, which is in line with injectable prophylactics. If confirmed in Phase 3, deucrictibant XR could emerge as a differentiated oral option in an increasingly competitive HAE landscape. Meanwhile, the acute franchise is de-risked with robust RAPIDe-3 data supporting an NDA submission this quarter. We assign deucrictibant a POS of 90% for HAE treatment and 70% in HAE prophylaxis, with peak sales of~$950M and ~ $1.6B, respectively.
0 · Reply
TwongStocks
TwongStocks May. 12 at 7:45 PM
$KALV Still waiting on Chiesi to commence the tender offer. Per the 8-K, Chiesi has to initiate the tender offer within 10 business days of the merger agreement. https://www.sec.gov/ix?doc=/Archives/edgar/data/0001348911/000114036126017656/ef20071670_8k.htm "The Merger Agreement provides that Purchaser will commence the Offer no later than 10 business days after the date of the Merger Agreement." Merger agreement was signed Apr 29. If my count is right, ten business days is May 13. Cheisi needs to commence the tender offer by tomorrow.
0 · Reply
Pukkaa56
Pukkaa56 May. 11 at 6:47 AM
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech May. 7 at 6:03 PM
$CPRX M&A valuation as multiples of Year 4 (FY29), 5-year & 10-year revenue estimates versus peer commercial-stage biopharma M&A exits. Peer multiples are calculated using the revenue forecasts prepared by the management/BOD of the acquiree. $KALV & $APLS also use analyst consensus. NOTE CPRX is being acquired at one of the highest 10-year multiples (very likely because CPRX is a much more mature commercial-stage bio versus most of the peers). We're merely sharing our analysis. This is not investment advice. We cannot think of any peer like CPRX (that sold multiple therapies) except for $XERS which has patent life considerations $XBI
4 · Reply
JuggernautRaider
JuggernautRaider May. 4 at 2:11 PM
$SNDX looking juicy for a buyout! I called $KALV and I’m calling Syndax too - not invested currently but may buy dips. GLB ☘️ 🐂
2 · Reply
BearTamerTrading
BearTamerTrading May. 1 at 5:52 PM
$KALV Another Potential Rocket rises to the occasion again ! Congratulations to all members who had access a week in advance one month ago before the public. As always thank you for your trust. I will continue to deliver tremendous value and ROI for just 49.99 a month. I Don’t Miss ! https://youtu.be/ajTV9H8J8ew?si=RsseynwHmvBWjUQ9
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech May. 1 at 1:47 AM
$KALV 's $1.9B M&A enterprise value = 0.93X 5-year analyst consensus & 0.34X 10-year consensus. This appears right down the middle v. peer comm'l-stage M&A exits. The attached table calculates KALV's multiples using analyst consensus where the 11 peers use revenue forecasts prepared by the acquiree's mgnt/BOD. $SNDX has a new analyst providing revenue forecasts, which are now meaningfully higher than last week. SNDX's forecasts are now so high we don't believe they are credible but WTF do we know. We'll wait until analysts swallow today's update before reposting SNDX multiples. All the same, at $20/share SNDX's risk v reward profile is now quite compelling if analyst estimates are credible. SNDX $58MM in Q126 R&D or $200MM+/year? Let's hope there's a return SNDX 5-year consensus FY26-30 now = $3.94B per Seeking Alpha. Put a 0.90 or a 1.0X like KALV? Higher/lower? $ACAD $TARS $ARDX trade @ multiples meaningfully lower than peers (again if analyst estimates are credible). Much more to come.
4 · Reply
Vwill33
Vwill33 May. 1 at 12:45 AM
$KALV anyone looking into NUVB?
0 · Reply
RainyDayFund
RainyDayFund Apr. 30 at 6:21 PM
$KALV So we wait until deal closes and they pay us $27 per share?
1 · Reply
IN0V8
IN0V8 Apr. 30 at 2:23 PM
$KALV Jonestrading cuts to hold rating Leerink Partners cuts to market perform from outperform Leerink Partners raises target to $27 from $22
0 · Reply
topstockalerts
topstockalerts Apr. 30 at 2:18 AM
Top Gainers PT2 $SIMO $RPGL $KALV $FCEL $JLHL
0 · Reply
JazzyJ03
JazzyJ03 Apr. 30 at 1:52 AM
0 · Reply
Vwill33
Vwill33 Apr. 30 at 1:10 AM
$KALV what’s next fam??? What else is everyone looking at
0 · Reply
Fundamentalist1
Fundamentalist1 Apr. 29 at 10:57 PM
0 · Reply
LewisDaKat
LewisDaKat Apr. 29 at 10:30 PM
$KALV Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement https://marketwirenews.com/stock/kalv/news/stock-market-today-april-29-kalvista-pharmaceuticals-7822154853393969.html?utm_source=stocktwits
0 · Reply
St0ckt0k101
St0ckt0k101 Apr. 29 at 10:15 PM
$KALV close enough!! Congrats folks‼️
0 · Reply
topstockalerts
topstockalerts Apr. 29 at 9:38 PM
Top Gainers PT2 $SIMO $RPGL $KALV $FCEL $JLHL
0 · Reply
History101
History101 Apr. 29 at 9:11 PM
$REPL many biotech stocks having a tough time right now, I am only keeping exposure now in a few of my favorites. $KALV was acquired today, so sold for a great gain, looking for where to deploy those gains. GLTALs!!
0 · Reply
History101
History101 Apr. 29 at 9:09 PM
$KALV acquired, so sold my position today for a great gain. Thank you KALV!! It's been great!! Will miss you!! On to the next one!!
0 · Reply
topstockalerts
topstockalerts Apr. 29 at 7:14 PM
Top Gainers PT2 $SIMO $KALV $RPGL $SAGT $MXL
0 · Reply
LewisDaKat
LewisDaKat Apr. 29 at 6:30 PM
$KALV Market Perform Recommendation Issued On KALV By Citigroup https://marketwirenews.com/stock/kalv/news/market-perform-recommendation-issued-on-kalv-by-citi-4771217282353339.html?utm_source=stocktwits
0 · Reply